Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;19(9):827-33.

Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial

Sarvin Sanaie  1 , Mehrangiz Ebrahimi-Mameghani  2 , Hadi Hamishehkar  3 , Mojtaba Mojtahedzadeh  4 , Ata Mahmoodpoor  5
Affiliations

Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial

Sarvin Sanaie et al. J Res Med Sci. 2014 Sep.

Abstract

Background: Impairment of intestinal barrier function and increased translocation of bacteria to the systemic blood flow contribute to the emergence of sepsis. Probiotics might be of beneficial effects on critically ill-patients, modulating intestinal barrier function and reducing inflammation. The aim of this trial was to determine the effect of probiotics on inflammatory markers in critically ill-patients in Intensive Care Unit (ICU).

Materials and methods: This trial was conducted on 40 critically ill-patients admitted to the ICU. Patients were randomly assigned to receive placebo or probiotic containing Lactobacillus, Bifidobacterium and Streptococcus thermophilus (VSL#3) for 7 days. Acute Physiology and Chronic Health Evaluation (APACHE II) score Sequential Organ Failure Assessment (SOFA) and systemic concentrations of interleukin-6 (IL-6), procalcitonin (PCT) and protein C were measured before initiation of the study and on days 4 and 7.

Results: A significant difference in IL-6 (P = 0.003), PCT (P = 0.014) and protein C (P < 0.001) levels, and also APACHE II and SOFA scores (P < 0.001) was seen over the treatment period between two groups. Moreover, there was a significant decrease in serum IL-6 levels (from 211.85 ± 112.76 to 71.80 ± 28.41) (P < 0.001) and PCT levels (from 1.67 ± 1.27 to 0.47 ± 0.41) (P < 0.001) and a significant increase in serum protein C levels (from 7.47 ± 3.61 to 12.87 ± 3.63) (P < 0.001) in probiotic group during the study.

Conclusion: Probiotics could reduce inflammation in critically ill-patients and might be considered as an adjunctive therapy in the treatment of critically ill-patients.

Keywords: Inflammation; probiotics; sepsis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Study overview (*Enteral nutrition)
Figure 2
Figure 2
Serum interleukin-6, procalcitonin and protein C levels during the different days of the study† Independent t-tes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54. - PubMed
    1. Centers for Disease Control (CDC). Increase in National Hospital Discharge Survey rates for septicemia – United States, 1979-1987. MMWR Morb Mortal Wkly Rep. 1990;39:31–4. - PubMed
    1. Eslami K, Mahmoodpoor A, Ahmadi A, Abdollahi M, Kamali K, Mousavi S, et al. Positive effect of septimeb™ on mortality rate in severe sepsis: A novel non antibiotic strategy. Daru. 2012;20:40. - PMC - PubMed
    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10. - PubMed
    1. Takala A, Nupponen I, Kylänpää-Bäck ML, Repo H. Markers of inflammation in sepsis. Ann Med. 2002;34:614–23. - PubMed